ProQR Therapeutics (PRQR) Invested Capital (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Invested Capital for 5 consecutive years, with $70.4 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 34.91% to $70.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.4 million through Dec 2025, down 34.91% year-over-year, with the annual reading at $70.4 million for FY2025, 34.91% down from the prior year.
  • Invested Capital hit $70.4 million in Q4 2025 for ProQR Therapeutics, down from $108.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $175.8 million in Q4 2021 to a low of $61.1 million in Q4 2023.
  • Historically, Invested Capital has averaged $99.8 million across 5 years, with a median of $83.5 million in 2022.
  • Biggest five-year swings in Invested Capital: crashed 52.47% in 2022 and later surged 76.84% in 2024.
  • Year by year, Invested Capital stood at $175.8 million in 2021, then plummeted by 52.47% to $83.5 million in 2022, then decreased by 26.8% to $61.1 million in 2023, then skyrocketed by 76.84% to $108.1 million in 2024, then plummeted by 34.91% to $70.4 million in 2025.
  • Business Quant data shows Invested Capital for PRQR at $70.4 million in Q4 2025, $108.1 million in Q4 2024, and $61.1 million in Q4 2023.